Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae.
about
Treatment of enteric fever (typhoid and paratyphoid fever) with third and fourth generation cephalosporinsFluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever)Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever)Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case seriesIn vitro activities of 11 fluoroquinolones against 816 non-typhoidal strains of Salmonella enterica isolated from Finnish patients with special reference to reduced ciprofloxacin susceptibility.Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhiEpidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella InfectionsGlobal trends in typhoid and paratyphoid FeverPopulation-based incidence of typhoid fever in an urban informal settlement and a rural area in Kenya: implications for typhoid vaccine use in AfricaUse of population-based surveillance to define the high incidence of shigellosis in an urban slum in Nairobi, KenyaPart I. Analysis of data gaps pertaining to Salmonella enterica serotype Typhi infections in low and medium human development index countries, 1984-2005.Emergence of multidrug-resistant Salmonella enterica serovar typhi in Korea.Fitness costs and stability of a high-level ciprofloxacin resistance phenotype in Salmonella enterica serotype enteritidis: reduced infectivity associated with decreased expression of Salmonella pathogenicity island 1 genesApplication of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhiSalmonella enterica serotype Virchow associated with human infections in Switzerland: 2004-2009.The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapySuitable disk antimicrobial susceptibility breakpoints defining Salmonella enterica serovar Typhi isolates with reduced susceptibility to fluoroquinolonesAntimicrobial susceptibility patterns of Salmonella enterica serotype typhi in eastern NepalAntimicrobial resistance among invasive nontyphoidal Salmonella enterica isolates in the United States: National Antimicrobial Resistance Monitoring System, 1996 to 2007.Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected adults and adolescents in northern Tanzania.Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected children and infants in northern TanzaniaAntimicrobial susceptibility of travel-related Salmonella enterica serovar Typhi isolates detected in Switzerland (2002-2013) and molecular characterization of quinolone resistant isolates.Increase in nalidixic acid resistance among non-Typhi Salmonella enterica isolates in the United States from 1996 to 2003.Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid feverEfficacy of Ciprofloxacin for Treatment of Cholera Associated with Diminished Susceptibility to Ciprofloxacin to Vibrio cholerae O1Plasmid-mediated quinolone resistance among non-Typhi Salmonella enterica isolates, USAAvailable options in the management of non-typhi Salmonella.Antimicrobial resistance in nontyphoid Salmonella serotypes: a global challenge.Setting and revising antibacterial susceptibility breakpoints.Salmonella enterica Serotype Typhi with nonclassical quinolone resistance phenotype.Nalidixic acid-resistant Salmonella enterica serotype Typhi presenting as a primary psoas abscess: case report and review of the literature.Antimicrobial resistance among Salmonella and Shigella isolates in five Canadian provinces (1997 to 2000)Fluoroquinolone Resistance in Salmonella and the Utility of Pefloxacin Disk Diffusion [corrected].Development of a Pefloxacin Disk Diffusion Method for Detection of Fluoroquinolone-Resistant Salmonella enterica.Use of antimicrobial agents in veterinary medicine and implications for human health.Enteric (typhoid) fever in travelers.Human health consequences of antimicrobial drug-resistant Salmonella and other foodborne pathogens.Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States foodnet multicenter retrospective cohort study.Interaction of silver nanoparticles with serum proteins affects their antimicrobial activity in vivo.
P2860
Q24200295-0EDE496F-F066-418E-A634-E6354169B8FEQ24236124-07021936-7E97-4F1A-A66E-5FBF047E3E17Q24236348-63D6EFA3-9390-4141-A655-8F532F21CD00Q24241024-4C93E4FA-25A1-4459-92CD-A9EE293AD9E8Q24796973-DFD17C5F-4ACB-46DC-8E9E-C1C3AF05968CQ24812949-6BEFD62F-FE5E-4281-8CFD-7BE0B467572EQ24814191-F82CF0F8-38BB-4B5C-BAFE-30A411C5CA39Q28084595-31112DC9-B248-4C5D-8476-14208560DF3CQ28267865-818D4F2C-7BCC-41AD-8AC4-C2F414586143Q28478975-ACDABF85-4655-4DB7-8403-0978639DF93DQ28487734-EF84C931-DFCB-4C36-8691-00C346C73ADFQ31121277-3C1FCEA4-CECE-4192-BF06-E5288B4064B4Q33208278-4311A907-0C4F-416D-83FB-3A596E469F1BQ33559090-02965CBD-ADE7-414A-BDAF-A9AB8A2FC10CQ33769931-3C64BA65-E878-47F6-9D16-92D70EC55D26Q33827595-603D558B-1E92-48F3-9438-0129E2BBB457Q33945463-F5E47623-91A0-4EBA-8D96-CFA596CA1999Q34309550-4C4D7C0C-02D0-46A8-976A-7D7B1716AA65Q34453931-E924DE82-1473-4777-9410-7D2CF1E31B31Q34737164-435F9F40-B261-4131-8380-3849F6114D0BQ35019855-DDEAF918-D479-47CE-B19D-A1011BA8C9F3Q35583353-A846A1B5-E20F-4769-BDD8-CDD1EFAF3E08Q35619395-2B5DF4A8-330A-4EAC-BF3F-C0759B99B254Q35635699-7EC34C06-F666-416B-8A24-A40E7CEF1F40Q35647804-557B21D9-37E1-40AB-9546-576B71DEC84EQ35745227-8184780A-AE29-4A9D-BF18-C30CDA562135Q35804933-E25FA4E2-5F82-4242-9FBB-4E925F1F5A55Q35841582-9E307808-F6AC-40C9-B3BD-525A26F1F9D5Q35882359-01A439F9-332E-4EC8-B2CC-2C7E21A8E483Q35913176-14CF79A7-C587-43B5-988C-FD3A136B1DE8Q35980113-057A353B-58B5-47F7-BC26-F89519BDD3D0Q36032699-9B7750C8-EF23-4733-B334-864C328D8722Q36171238-7F7D7FCC-FAEF-4F79-84EE-CD26CD414C40Q36173899-D425ADF3-0C52-4356-964D-C99410A0CF25Q36173968-A941823C-157E-45BF-AC72-CD651E652CFEQ36260950-4E2E1CD3-606B-4993-AC59-217CD6DFDB50Q36289065-DF5DE9C8-A990-4C32-BD3A-6DD27BF44940Q36305522-63BC0567-EBA4-4022-954A-A48BB3204900Q36538683-02DFF731-3E9D-425E-B4D4-18E43E20E55DQ37263740-D0D3DFB0-2202-4604-9359-E4F74BE8AA92
P2860
Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Reevaluating fluoroquinolone b ...... and for non-Typhi salmonellae.
@en
type
label
Reevaluating fluoroquinolone b ...... and for non-Typhi salmonellae.
@en
prefLabel
Reevaluating fluoroquinolone b ...... and for non-Typhi salmonellae.
@en
P2860
P356
P1476
Reevaluating fluoroquinolone b ...... and for non-Typhi salmonellae.
@en
P2093
Jennifer T Nelson
Timothy J Barrett
P2860
P356
10.1086/375602
P407
P577
2003-06-20T00:00:00Z